Advertisement

Topics

Actelion Company Profile

11:42 EST 22nd November 2017 | BioPortfolio

Actelion Ltd, a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream.

Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs.

Location

Gewerbestrasse 16
Allschwil
CH 4123
Switzerland

Contact

Phone: +41 61 487 4545
Fax: +41 61 487 4500


News Articles [26 Associated News Articles listed on BioPortfolio]

SMC bars access to Actelion’s Uptravi on NHS Scotland

Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.

Actelion’s Reincarnation Comes Out Swinging with Phase II Success in Insomnia

Actelion’s successor Idorsia reported its candidate for insomnia met the primary endpoint in Phase II and will advance to Phase III. In its first report from the clinic last Friday, Idorsia anno...

Actelion-Aktien werden per 7. November 2017 dekotiert - letzter Handelstag 6.11.

Zürich (awp) - Die SIX Swiss Exchange hat das Datum der schon länger erwarteten Dekotierung der Actelion-Aktien festgelegt. Die Aktie wird demnach per 7. November 2017 dekotiert, der letzte Handels....

Zukauf und neue Krebsmittel kurbeln das Geschäft an: Die Übernahme von Actelion wirkt sich bereits im ...

Die Übernahme von Actelion wirkt sich bereits im ersten Quartal nach Abschluss der Transaktion positiv auf die Zahlen von Johnson & Johnson aus. Der Pharmakonzern überrascht die Analysten. An der B....

Actelion receives FDA approval for 32mg Tracleer to treat paediatric PAH patients

Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson & Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patient...

Christoph Schmidt, Corporate VP Global Head of Commercial Excellence, Actelion Pharmaceuticals

Christoph Schmidt, Corporate VP Global Head of Commercial Excellence, Actelion Pharmaceuticals

Actelion Receives FDA Approval Of TRACLEER (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension

  Life Sciences Jobs   ...

Actelion First Quarter Net Profit Falls Sharply in ‘Challenging’ Marketplace

Biotech company has high hopes for forthcoming drug trial despite revenue decline.

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Ventavis [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VENTAVIS safely and effectively. See full prescribing information for VENTAVIS. VENTAVIS (iloprost) inhalation solution Initial U.S. A...

Veletri [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VELETRI safely and effectively. See full prescribing information for VELETRI. VELETRI (epoprostenol) for Injection Initial U.S. Approv...

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means f...

Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension

The main objective of the study is to explore the effects of ERA - at different dose strengths - on the efficacy, safety and tolerability in subjects with essential hypertension

Companies [4 Associated Companies listed on BioPortfolio]

Actelion Pharmaceuticals Ltd

Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources, based on first-in class small molecule compounds. In doing so, Actelion is focussing on innovati...

Actelion Pharmaceuticals US, Inc.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor a...

Actelion

Actelion Ltd, a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, is a leading player in innovative science related to the endothelium - the single layer of cells separating e...

Actelion Ltd

Dr. McLaughlin is currently the professor of medicine and director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan in Ann Arbor, Michigan...

More Information about "Actelion" on BioPortfolio

We have published hundreds of Actelion news stories on BioPortfolio along with dozens of Actelion Clinical Trials and PubMed Articles about Actelion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Actelion Companies in our database. You can also find out about relevant Actelion Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record